QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2028

Conditions

TNBC, Triple Negative Breast Cancer

Interventions

DRUG

bevacizumab

DRUG

QL1706

Bispecific antibody (bsAB) targeting PD-1 and CLTA-4

DRUG

Nab paclitaxel

albumin-bound paclitaxel

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER